Bedrijfsoverzicht
Trinity Biotech plc is a specialized entity within the healthcare sector, specifically operating in the medical devices industry where it focuses on the acquisition, development, manufacture, and marketing of diagnostic products. The company targets the clinical laboratory and point-of-care segments across major global regions including the Americas, Asia, Africa, and Europe, thereby establishing a broad international footprint for its diagnostic solutions. As of the latest available data, the company holds a market capitalization of $13.50M and employs a workforce of 401 individuals to support its operational scope. With an annual revenue of $48.57M, the organization operates at a relatively small scale compared to industry giants, which is reflected in its modest market valuation and limited revenue generation. These figures indicate that Trinity Biotech functions as a mid-to-small-cap player that is likely navigating the competitive diagnostic market with a specific product focus rather than broad diversification, resulting in a capital structure that reflects early-stage or specialized growth characteristics rather than mature market dominance.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $48.57M, yet this top-line figure contrasts sharply with a net income loss of $36,283,000, revealing a significant gap that highlights substantial operating expenses or non-operating charges eroding profitability. EBITDA for the period stood at $-14,029,000, further underscoring the challenges in covering operational costs before interest and taxes, while free cash flow was negative at $-7,285,750, indicating a current lack of financial flexibility to fund operations or capital expenditures without external financing. The gross margin stands at 36.8%, suggesting that the cost of goods sold consumes a significant portion of revenue, yet the operating margin of -3.6% and profit margin of -75.9% demonstrate that overhead costs and other expenses are aggressively impacting the bottom line. On the balance sheet, the company holds $1.34M in cash against total debt of $117.20M, a disparity that signals a highly leveraged position, while the debt-to-equity ratio is listed as N/A, implying that equity may be negligible or the company is structured in a way that renders this traditional metric inapplicable. The current ratio is 1.03, which indicates that the company possesses just enough current assets to cover its current liabilities, suggesting a tight liquidity position with little room for error in short-term cash management. Furthermore, the return on equity is N/A and the return on assets is -9.5%, metrics that collectively reveal that management is currently failing to generate positive returns on the capital employed or the asset base, pointing to significant operational inefficiencies or a temporary phase of heavy investment that has not yet yielded financial rewards.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is -0.69, a figure that mathematically implies an expectation of continued losses or a revaluation of earnings that has not yet materialized in the trailing period. The price-to-book ratio is -0.24, a negative figure that suggests the company's market value is below its book value, often seen in distressed situations or entities with significant intangible assets not fully captured on the balance sheet, rather than indicating a standard market premium. Additionally, the price-to-sales ratio is 0.28 and the EV/EBITDA is -27.26, alternative metrics that suggest the market is pricing the stock based on revenue multiples rather than earnings power, potentially valuing the company on its growth potential or asset base despite current unprofitability. In terms of trading range, the 52-week high is $3.44 and the 52-week low is $0.50, providing a context for price volatility where the current share price sits significantly below the annual peak, reflecting a prolonged period of downward pressure or consolidation. The beta value is 0.79, indicating that the stock's price volatility is lower than the broader market benchmark, suggesting that Trinity Biotech plc moves less drastically in response to general market swings compared to large-cap equities.
Growth & Income
Regarding growth dynamics, the revenue growth year-over-year is -5.5%, while earnings growth is N/A due to the absence of prior period positive earnings for comparison; this implies that the company is currently in a contraction phase regarding top-line sales rather than a period of expansion. Since the company reports a dividend yield of N/A and a payout ratio of 0.0%, it is classified as a non-dividend payer, which means the organization retains all available cash flow to reinvest into research, development, or debt reduction rather than distributing income to shareholders. The combination of negative revenue growth and a zero dividend policy indicates a strategic focus on survival and operational restructuring rather than income generation for investors. Overall, Trinity Biotech plc currently presents a profile characterized by declining revenue, significant cash burn, and no income distribution, positioning it as a high-risk, high-volatility investment within the medical device sector that relies on future turnaround potential rather than current profitability or income yields.